My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

60.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Guardant Health to Report First Quarter Financial Results on May 5, 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting
From Guardant Health, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Recap: Guardant Health Q4 Earnings
Guardant Health (NASDAQ:GH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:03 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
From Guardant Health, Inc.
Via Business Wire
Guardant Health Response to Frivolous and Retaliatory Lawsuit Filed by Illumina
From Guardant Health, Inc.
Via Business Wire
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
From Guardant Health, Inc.
Via Business Wire
Guardant Health's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q4, Guardant Health's (NASDAQ:GH) reported sales totaled $108.11 million. Despite a 32.75% increase in earnings, the company posted a... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading. 
Via Benzinga
Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook
From Guardant Health, Inc.
Via Business Wire
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
From Guardant Health, Inc.
Via Business Wire
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
From Guardant Health, Inc.
Via Business Wire
Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation
From Guardant Health, Inc.
Via Business Wire
Why Jim Cramer Likes Vertiv And Scotts Miracle-Gro
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Vertiv Holdings Co (NYSE: 
Via Benzinga
Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360® Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
68 Biggest Movers From Wednesday
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (... 
Via Benzinga
Topics Initial Public Offering
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical
If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force... 
Via FinancialNewsMedia
Guardant Health to Participate in the 2021 Stifel Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Registers 27% Revenue Growth In Q3, Tops Consensus; Backs FY21 Guidance
Guardant Health Inc (NASDAQ: GH) reported Q3 sales of $94.8 million, +27% Y/Y, beating the Wall Street estimate of $92.64 million. Guardant's Q3 precision oncology... 
Via Benzinga
Guardant Health Inc (GH) Q3 2021 Earnings Call Transcript
GH earnings call for the period ending October 30, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.